|
Vaccine Detail
Belagenpumatucel-L |
Vaccine Information |
- Vaccine Name: Belagenpumatucel-L
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007329
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TGFB2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preservative: Belagenpumatucel-L is an allogeneic non small cell lung cancer (NSCLC) cells transfected with a TGF-β2 antisense gene plasmid (Nemunaitis et al., 2009; Nemunaitis et al., 2006; Fakhrai et al., 2006)
- Description: A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. (NCIT_C73438). This vaccine has been used in clinical trials involving NSCLC. (Rijavec et al., 2015)
|
Host Response |
|
References |
Fakhrai et al., 2006: Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer gene therapy. 2006; 13(12); 1052-1060. [PubMed: 16826191].
NCIT_C73438: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73438]
Nemunaitis et al., 2006: Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(29); 4721-4730. [PubMed: 16966690].
Nemunaitis et al., 2009: Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer gene therapy. 2009; 16(8); 620-624. [PubMed: 19287371].
Rijavec et al., 2015: Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F. Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert opinion on biological therapy. 2015; 15(9); 1371-1379. [PubMed: 26211534].
|
|